Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer

Cancer and Metastasis Reviews

Volumn 26, Issue 3-4, 2007, Pages 579-585

  Wu, Gen Sheng ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; MAPKs; MKP

Indexed keywords

CHELERYTHRINE; CISPLATIN; DEHYDRODIDEMNIN B; GLUCOCORTICOID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PHOSPHATASE; SANGUINARINE; TAMOXIFEN;

BREAST CANCER; CANCER GROWTH; CANCER THERAPY; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; LUNG CANCER; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

ANIMALS; DUAL SPECIFICITY PHOSPHATASE 1; DUAL SPECIFICITY PHOSPHATASE 6; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; NEOPLASMS;

EID: 36148978132     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9079-6     Document Type: Review

References (66)

1. Davis, R. J. (2000). Signal transduction by the JNK group of MAP kinases. Cell, 103, 239-252.
2. Johnson, G. L., & Lapadat, R. (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 298, 1911-1912.
3. Pearson, G., Robinson, F., Beers Gibson, T., Xu, B., Karandikar, M., Berman, K., et al. (2001). Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocrine Reviews, 22, 153-183.
4. Chang, L., & Karin, M. (2001). Mammalian MAP kinase signalling cascades. Nature, 410, 37-40.
5. Kennedy, N. J., & Davis, R. J. (2003). Role of JNK in tumor development. Cell Cycle, 2, 199-201.
6. Camps, M., Nichols, A., & Arkinstall, S. (2000). Dual specificity phosphatases: A gene family for control of MAP kinase function. FASEB Journal, 14, 6-16.
7. Dickinson, R. J., & Keyse, S. M. (2006). Diverse physiological functions for dual-specificity MAP kinase phosphatases. Journal of Cell Science, 119(Pt 22), 4607-4615.
8. Kondoh, K., & Nishida, E. (2006). Regulation of MAP kinases by MAP kinase phosphatases. Biochim Biophys Acta, 1773(8), 1227-1237.
9. Zhan, X. L., Wishart, M. J., & Guan, K. L. (2001). Nonreceptor tyrosine phosphatases in cellular signaling: Regulation of mitogen-activated protein kinases. Chemical Reviews, 101(8), 2477-2496.
10. Theodosiou, A., & Ashworth, A. (2002). MAP kinase phosphatases. Genome Biology, 3(7), REVIEWS3009.
11. Rohan, P. J., Davis, P., Moskaluk, C. A., Kearns, M., Krutzsch, H., Siebenlist, U., et al. (1993). PAC-1: A mitogen-induced nuclear protein tyrosine phosphatase. Science, 259(5102), 1763-1766.
12. Muda, M., Boschert, U., Smith, A., Antonsson, B., Gillieron, C., Chabert, C., et al. (1997). Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4. Journal of Biological Chemistry, 272(8), 5141-5151.
13. Lau, L. F., & Nathans, D. (1985). Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells. EMBO Journal, 4(12), 3145-3151.
14. Charles, C. H., Abler, A. S., & Lau, L. F. (1992). cDNA sequence of a growth factor-inducible immediate early gene and characterization of its encoded protein. Oncogene, 7, 187-190.
15. Keyse, S. M., & Emslie, E. A. (1992). Oxidative stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase. Nature, 359, 644-647.
16. Li, J., Gorospe, M., Hutter, D., Barnes, J., Keyse, S. M., & Liu, Y. (2001). Transcriptional induction of MKP-1 in response to stress is associated with histone H3 phosphorylation-acetylation. Molecular and Cellular Biology, 21, 8213-8224.
17. Liu, Y., Gorospe, M., Yang, C., & Holbrook, N. J. (1995). Role of mitogen-activated protein kinase phosphatase during the cellular response to genotoxic stress. Inhibition of c-Jun N-terminal kinase activity and AP-1-dependent gene activation. Journal of Biological Chemistry, 270(15), 8377-8380.
18. Zhou, J. Y., Liu, Y., & Wu, G. S. (2006). The role of mitogen-activated protein kinase phosphatase-1 in oxidative damage-induced cell death. Cancer Research, 66(9), 4888-4894.
19. Wang, Z., Xu, J., Zhou, J. Y., Liu, Y., & Wu, G. S. (2006). Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Research, 66(17), 8870-8877.
20. Sun, H., Charles, C. H., Lau, L. F., & Tonks, N. K. (1993). MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell, 75, 487-493.
21. Noguchi, T., Metz, R., Chen, L., Mattei, M. G., Carrasco, D., & Bravo, R. (1993). Structure, mapping, and expression of erp, a growth factor-inducible gene encoding a nontransmembrane protein tyrosine phosphatase, and effect of ERP on cell growth. Molecular and Cellular Biology, 13, 5195-5205.
22. Franklin, C. C., & Kraft, A. S. (1997). Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. Journal of Biological Chemistry, 272, 16917-16923.
23. Brondello, J. M., McKenzie, F. R., Sun, H., Tonks, N. K., Pouyssegur, J. (1995). Constitutive MAP kinase phosphatase (MKP-1) expression blocks G1 specific gene transcription and S-phase entry in fibroblasts. Oncogene, 10, 1895-1904.
24. Li, M., Zhou, J. Y., Ge, Y., Matherly, L. H., & Wu, G. S. (2003). The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. Journal of Biological Chemistry, 278, 41059-41068.
25. Yang, H., & Wu, G. S. (2004). p53 Transactivates the phosphatase MKP1 through both intronic and exonic p53 responsive elements. Cancer Biology and Therapy, 3(12), 1277-1282.
26. Wu, G. S. (2004). The Functional Interactions Between the p53 and MAPK Signaling Pathways. Cancer Biology and Therapy, 3, 156-161.
27. Franklin, C. C., Srikanth, S., & Kraft, A. S. (1998). Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. Proceedings of the National Academy of Sciences, U.S.A., 95, 3014-3019.
28. Sanchez-Perez, I., Martinez-Gomariz, M., Williams, D., Keyse, S. M., & Perona, R. (2000). CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene, 19, 5142-5152.
29. Wu, J. J., & Bennett, A. M. (2005). Essential role for MAP kinase phosphatase-1 in stress-responsive MAP kinase and cell survival signaling. Journal of Biological Chemistry, 280, 16461-16466.
30. Chattopadhyay, S., Machado-Pinilla, R., Manguan-Garcia, C., Belda-Iniesta, C., Moratilla, C., Cejas, P., et al. (2006). MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene, 25(23), 3335-3345.
31. Dorfman, K., Carrasco, D., Gruda, M., Ryan, C., Lira, S. A., & Bravo, R. (1996). Disruption of the erp/mkp-1 gene does not affect mouse development: Normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene, 13, 925-931.
32. Wang, H. Y., Cheng, Z., & Malbon, C. C. (2003). Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Letters, 191(2), 229-237.
33. Loda, M., Capodieci, P., Mishra, R., Yao, H., Corless, C., Grigioni, W., et al. (1996). Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. American Journal of Pathology, 149(5), 1553-1564.
34. Vicent, S., Garayoa, M., Lopez-Picazo, J. M., Lozano, M. D., Toledo, G., Thunnissen, F. B., et al. (2004). Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clinical Cancer Research, 10(11), 3639-3649.
35. Denkert, C., Schmitt, W. D., Berger, S., Reles, A., Pest, S., Siegert, A., et al. (2002). Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. International Journal of Cancer, 102(5), 507-513.
36. Manzano, R. G., Montuenga, L. M., Dayton, M., Dent, P., Kinoshita, I., Vicent, S., et al. (2002). CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene, 21(28), 4435-4447.
37. Rauhala, H. E., Porkka, K. P., Tolonen, T. T., Martikainen, P. M., Tammela, T. L., & Visakorpi, T. (2005). Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer. International Journal of Cancer, 117(5), 738-745.
38. Liao Q., Guo J., Kleeff J., Zimmermann, A., Büchler, M. W., Korc, M., et al. (2003). Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology, 124(7), 1830-1845.
39. Tsujita, E., Taketomi, A., Gion, T., Kuroda, Y., Endo, K., Watanabe, A., et al. (2005). Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma. Oncology, 69(4), 342-347.
40. Yokoyama, A., Karasaki, H., Urushibara, N., Nomoto, K., Imai, Y., Nakamura, K., et al. (1997). The characteristic gene expressions of MAPK phosphatases 1 and 2 in hepatocarcinogenesis, rat ascites hepatoma cells, and regenerating rat liver. Biochemical and Biophysical Research Communications, 239(3), 746-751.
41. Bang, Y. J., Kwon, J. H., Kang, S. H., Kim, J. W., & Yang, Y. C. (1998). Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma. BBRC, 250(1), 43-47.
42. Groom, L. A., Sneddon, A. A., Alessi, D. R., Dowd, S., & Keyse, S. M. (1996). Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO Journal, 15(14), 3621-3632.
43. Muda, M., Boschert, U., Dickinson, R., Martinou, J.-C., Martinou, I., Camps, M., et al. (1996). MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. Journal of Biological Chemistry, 271(8), 4319-4326.
44. Kawakami, Y., Rodriguez-Leon, J., Koth, C. M., Büscher, D., Itoh, T., Raya, A., et al. (2003). MKP3 mediates the cellular response to FGF8 signalling in the vertebrate limb. Nature Cell Biology, 5(6), 513-519.
45. Furukawa, T., Sunamura, M., Motoi, F., Matsuno, S., & Horii, A. (2003). Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. American Journal of Pathology, 162(6), 1807-1815.
46. Furukawa, T., Fujisaki, R., Yoshida, Y., Kanai, N., Sunamura, M., Abe, T., et al. (2005). Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Modern Pathology, 18(8), 1034-1042.
47. Xu, S., Furukawa, T., Kanai, N., Sunamura, M., & Horii, A. (2005). Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. Journal of Human Genetics, 50(4), 159-167.
48. Marchetti, S., Gimond, C., Roux, D., Gothie, E., Pouyssegur, J., & Pages, G. (2004). Inducible expression of a MAP kinase phosphatase-3-GFP chimera specifically blunts fibroblast growth and ras-dependent tumor formation in nude mice. Journal of Cellular Physiology, 199(3), 441-450.
49. Chen, H. Y., Yu, S. L., Chen, C. H., Chang, G.-C., Chen, C.-Y., Yuan, A., et al. (2007). A five-gene signature and clinical outcome in non-small-cell lung cancer. New England Journal of Medicine, 356(1), 11-20.
50. Givant-Horwitz, V., Davidson, B., Goderstad, J. M., Nesland, J. M., Trope, C. G., & Reich, R. (2004). The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecologic Oncology, 93(2), 517-523.
51. Sieben, N. L., Oosting, J., Flanagan, A. M., Prat, J., Roemen,G. M. J. M., Kolkman-Uljee, S. M., et al. (2005). Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. Journal of Clinical Oncology, 23(29), 7257-7264.
52. Levy-Nissenbaum, O., Sagi-Assif, O., Kapon, D., Hantisteanu, S., Burg, T., Raanani, P., et al. (2003). Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells. Oncogene, 22(48), 7649-7660.
53. Levy-Nissenbaum, O., Sagi-Assif, O., Raanani, P., Avigdor, A., Ben-Bassat, I., & Witz, I. P. (2003). Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. Cancer Letters, 199(2), 185-192.
54. Srikanth, S., Franklin, C. C., Duke, R. C., & Kraft, A. S. (1999). Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Molecular and Cellular Biochemistry, 199, 169-178.
55. Orlowski, R. Z., Small, G. W., & Shi, Y. Y. (2002). Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. Journal of Biological Chemistry, 277(31), 27864-27871.
56. Small, G. W., Shi, Y. Y., Edmund, N. A., Somasundaram, S., Moore, D. T., & Orlowski, R. Z. (2004). Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Molecular Pharmacology, 66(6), 1478-1490.
57. Wu, W., Chaudhuri, S., Brickley, D. R., Pang, D., Karrison, T., & Conzen, S. D. (2004). Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Research, 64(5), 1757-1764.
58. Wu, W., Pew, T., Zou, M., Pang, D., & Conzen, S. D. (2005). Glucocorticoid receptor-induced MAPK phosphatase-1 (MKP-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. Journal of Biological Chemistry, 280(6), 4117-4124.
59. Cui, Y., Parra, I., Zhang, M., Hilsenbeck, S. G., Tsimelzon, A., Furukawa, T., et al. (2006). Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: A mechanism of tamoxifen resistance. Cancer Research, 66(11), 5950-5959.
60. Vogt, A., Cooley, K. A., Brisson, M., Tarpley, M. G., Wipf, P., & Lazo, J. S. (2003). Cell-active dual specificity phosphatase inhibitors identified by high-content screening. Chemistry and Biology, 10(8), 733-742.
61. Lazo, J. S., Nunes, R., Skoko, J. J., Queiroz de Oliveira, P. E., Vogt, A., & Wipf, P. (2006). Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1. Bioorganic & Medicinal Chemistry, 14(16), 5643-5650.
62. Vogt, A., Tamewitz, A., Skoko, J., Sikorski, R. P., Giuliano, K. A., & Lazo, J. S. (2005). The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. Journal of Biological Chemistry, 280(19), 19078-19086.
63. Arnold, D. M., Foster, C., Huryn, D. M., Lazo, J. S., Johnston,P. A., & Wipf, P. (2007). Synthesis and biological activity of a focused library of mitogen-activated protein kinase phosphatase inhibitors. Chemical Biology and Drug Design, 69(1), 23-30.
64. Chen, P., Li, J., Barnes, J., Kokkonen, G. C., Lee, J. C., & Liu, Y. (2002). Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. Journal of Immunology, 169, 6408-6416.
65. Wang, X., Matta, R., Shen, G., Nelin, L. D., Pei, D., & Liu, Y. (2006). Mechanism of triptolide-induced apoptosis: Effect on caspase activation and Bid cleavage and essentiality of the hydroxyl group of triptolide. Journal of Molecular Medicine, 84(5), 405-415.
66. Gonzalez-Santiago, L., Suarez, Y., Zarich, N., Muñoz-Alonso,M. J., Cuadrado, A., Martínez, T., et al. (2006). Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death and Differentiation, 13(11), 1968-1981.